Lenacapavir Intensification to Disrupt HIV Reservoirs in Virologically Suppressed People With HIV Receiving Antiretroviral Therapy

NCT06819176 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

50

Enrollment

NIH

Sponsor class

Conditions

Human Immunodeficiency Virus

Interventions

DRUG: Lenacapavir

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)